argenx SE Files 6-K Report
Ticker: ARGX · Form: 6-K · Filed: Oct 15, 2024 · CIK: 1697862
Sentiment: neutral
Topics: sec-filing, 6-K, business-update
TL;DR
argenx SE filed a 6-K report on Oct 15, 2024, providing business and financial updates.
AI Summary
On October 15, 2024, argenx SE issued a press release to report on its business and financial updates. The company, headquartered in Amsterdam, the Netherlands, is a biopharmaceutical firm focused on developing treatments for severe autoimmune diseases and cancer. This filing is a routine report under the Securities Exchange Act of 1934.
Why It Matters
This filing provides an update on argenx SE's business and financial activities, which is important for investors to stay informed about the company's progress and any material developments.
Risk Assessment
Risk Level: low — This is a routine SEC filing (Form 6-K) that reports on business and financial updates, not a filing that typically introduces new or significant risks.
Key Players & Entities
- argenx SE (company) — Registrant
- October 15, 2024 (date) — Date of press release and filing
- Amsterdam, the Netherlands (location) — Principal executive offices
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report on business and financial updates issued by argenx SE via a press release on October 15, 2024.
When was the press release mentioned in the filing issued?
The press release was issued on October 15, 2024.
Where are argenx SE's principal executive offices located?
argenx SE's principal executive offices are located at Laarderhoogtweg 25, 1101 EB Amsterdam, the Netherlands.
What type of company is argenx SE?
argenx SE is a biopharmaceutical company, with a Standard Industrial Classification of Biological Products (No Diagnostic Substances).
Under which rule is this Form 6-K filed?
This Form 6-K is filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Filing Stats: 289 words · 1 min read · ~1 pages · Grade level 13.6 · Accepted 2024-10-15 08:14:04
Filing Documents
- tm2426138d1_6k.htm (6-K) — 11KB
- tm2426138d1_ex99-1.htm (EX-99.1) — 70KB
- image_004.jpg (GRAPHIC) — 2KB
- 0001104659-24-108362.txt ( ) — 85KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ARGENX SE Date: October 15, 2024 By: /s/ Hemamalini (Malini) Moorthy Name: Hemamalini (Malini) Moorthy Title: General Counsel